Carlsquare Equity Research inleder bevakning av vaccinbolaget Abera Bioscience AB (”Abera” eller ”Bolaget”) och publicerar idag en initieringsanalys på bolaget.
Analysen kan laddas ner och läsas i sin helhet på Carlsquares hemsida:
https://carlsquare.com/sv/initieringsanalys-abera-bioscience-avancerar-med-ny-vaccinteknologi/
Get in contact with us via the contact form or email: info@aberabio.com
Abera Bioscience is a platform and vaccine development company based on over 30 years of research in the medical, molecular and microbiological field. Abera was founded in 2012 as a spin-out from the Swedish protein production company Xbrane Bioscience.